Lokesh Bhardwaj Law Offices ← Articles
Lokesh Bhardwaj Law Offices · Advocates and Legal Consultants, New Delhi · lokeshbhardwajlawoffices.com
Insurance Law · Article

When the insurer denies the best treatment available to you

Why the medical regulator's approval, not the underwriter's exclusion clause, decides what counts as treatment in India.

23 May 202612 minute read
Last reviewed: 17/10/2026
REGULATOR’S APPROVAL CDSCO · ICMR · NMC EXCLUSION CLAUSE drafted years ago where the regulator has spoken, the clause does not survive
The medical regulator's approval pre-empts the insurer's contractual classification. The exclusion clause does not survive the regulatory determination.

Your father needs a cardiac procedure. The cardiologist, with a degree from AIIMS and twenty years at a tertiary hospital, recommends angioplasty with drug-eluting stenting. He explains that the procedure is minimally invasive, that recovery is six to eight weeks shorter than open-heart surgery, that the risk of complications is materially lower, and that long-term outcomes are comparable to a bypass. Your father agrees. The hospital schedules the procedure. The pre-authorisation request goes to the insurance company.

The insurer's response arrives the next morning. The procedure is approved, but only at the rate applicable to open-heart bypass surgery. The cost of the stenting itself, the catheterisation laboratory charges, the imported stent, the specialised cardiologist's fee, all of which are documented and reasonable, will not be reimbursed. The insurer's logic, spelled out in three pages of fine print, is that the policy was drafted on a particular framework of "covered procedures," and the framework is now twelve years old.

Welcome to Indian health insurance, 2026.

The pattern repeats across the body of medicine. The urologist recommends a Holmium laser enucleation for the enlarged prostate. The insurer offers to pay only for the open prostatectomy. The oncologist recommends monoclonal antibody immunotherapy for the breast cancer. The insurer offers to pay only for the chemotherapy, and even that under a sub-limit drafted in 2015. The neurosurgeon recommends stereotactic radio-surgery for the brain tumour. The insurer offers to pay only for the craniotomy. A gene therapy receives Indian regulatory approval after a decade of clinical trials. The insurer says the treatment is too new and is not covered under the policy.

In each case, the patient is told he is free to choose. He is reminded that the policy is contractual and that he agreed to the terms. He is informed that if he wants the modern procedure, he is welcome to pay the difference himself. The difference, for any serious illness, runs into many lakhs. For some procedures it runs into tens of lakhs. Most patients cannot pay. Most patients accept the older procedure. And the older procedure, in too many cases, costs more in recovery, in complications, in lost years of life, in repeat admissions, than the insurer ever saved by denying the modern one.

This is the position of the Indian patient today. It rests on a question that has never been put plainly enough. Who decides what treatment you receive? The patient thinks it is his doctor. He is wrong. It is, in practice, the insurance company that took his premium for the last sixteen years.

❖ ❖ ❖

I. Who is supposed to decide

The decision of what counts as legitimate medical treatment in India is not an open question. It has been answered, by legislation and by institutional practice, in favour of a small set of medical regulators whose mandate is precisely this.

The Central Drugs Standard Control Organisation, constituted under the Drugs and Cosmetics Act, 1940, is the regulator of pharmaceuticals and medical devices in India. Every drug sold here is licensed by the CDSCO. Every imported drug is reviewed by it. The clinical trials that precede a drug's approval are overseen by it. When the CDSCO has approved a drug for a particular indication, that approval is the considered determination of the Indian State that the drug is safe enough, and effective enough, for use on Indian patients.

The Indian Council of Medical Research, the apex biomedical research body of the country, sets research priorities, issues standard treatment guidelines, and publishes evidence-based protocols. When the ICMR has endorsed a protocol, the medical community of India treats that endorsement as authoritative. The National Medical Commission, successor to the Medical Council of India, regulates the practice of medicine. Its norms on continuing medical education define what every Indian doctor is expected to know.

Beyond these statutory regulators sits the institutional consensus of the major teaching hospitals. AIIMS. The Tata Memorial Centre. PGIMER Chandigarh. CMC Vellore. NIMHANS Bangalore. SGPGI Lucknow. These are the places where Indian medicine is practised at the frontier. Their treatment protocols, peer-reviewed and revised every few years, become the standard of care that defines what an Indian doctor practising in 2026 is expected to offer her patient.

This is the apparatus that determines what counts as medical treatment in India. It does not include the underwriter who priced your policy.

The insurance company is not a medical regulator. It does not have a pharmacology department. It does not run clinical trials. It does not write treatment guidelines. It does not contribute to the standard of care. It is a financial institution that pools risk and pays claims. Its expertise is actuarial, not medical. The determination of what counts as a valid treatment for cancer, or for heart disease, or for any condition known to medicine, is not within its competence to make.

And yet, in policy after policy, the insurer is making exactly that determination. It is deciding what is modern and what is experimental. It is deciding which laser is acceptable and which is not. It is deciding which monoclonal antibody is part of standard practice and which is too new. It is, in effect, sitting as a parallel medical regulator, with no statutory mandate to do so, and using its veto to deny coverage to the modalities it does not wish to pay for. This is not a regulatory gap. This is a regulatory failure.

II. The regulator's duty

The Insurance Regulatory and Development Authority of India is a statutory body. It was constituted under Section 3 of the IRDA Act, 1999. On the settled test laid down in Pradeep Kumar Biswas v. Indian Institute of Chemical Biology, (2002) 5 SCC 111, it is an instrumentality of the State. It is "State" within the meaning of Article 12 of the Constitution of India.

That status is not ornamental. It carries a duty. The duty is to exercise the powers conferred by Section 34(1) of the Insurance Act, 1938 and Section 14(2)(e) of the IRDA Act, 1999 to ensure that the insurance policies sold to Indian citizens serve the purpose for which insurance exists. That purpose is the protection of the policyholder's life and health against the financial consequences of illness. It is not the maximisation of insurer profits. It is not the preservation of antiquated treatment menus. It is the protection of the citizen.

The duty is also constitutional. The Hon'ble High Court of Kerala has recently held, in Dr. A.M. Muraleedharan v. Senior Divisional Manager, Life Insurance Corporation of India, 2025 SCC OnLine Ker 8566, decided on 08.09.2025, that the arbitrary denial of a medical insurance claim violates Article 21 of the Constitution. The Court observed:

The right to medical treatment is a right identified under fundamental rights. Once the insured has undergone treatment or a surgical procedure on the expert opinion of the concerned doctor, the insurer cannot deny the claim. Rejection of the claim for the expenses incurred for such treatment availed by the insured amounts to denial of treatment.

The principle that emerges is this. A denial of a medical insurance claim is not a private contractual dispute between two parties. It is, in cases of arbitrary denial, an interference with a fundamental right. And the regulator that has been entrusted with the supervision of the insurance industry has a corresponding constitutional duty to prevent that interference.

The IRDAI has taken some steps in this direction. The Guidelines on Standardisation of Exclusions in Health Insurance Contracts, dated 27.09.2019, mandated coverage of twelve modern treatments that no health insurance policy in India may exclude. Robotic surgery. Stereotactic radio-surgery. Deep brain stimulation. Laser prostate vaporisation. Oral chemotherapy. Monoclonal antibody immunotherapy. Intra-vitreal injections. Bronchial thermoplasty. Intra-operative neuro monitoring. Uterine artery embolisation with HIFU. Balloon sinuplasty. Haematopoietic stem cell therapy for bone marrow transplant. The list was a recognition by the regulator that these treatments are no longer experimental, that they are part of established medical practice in India, and that the insurer's claim to the contrary cannot stand.

The Master Circular on Health Insurance Business, dated 29.05.2024, has reiterated and strengthened this mandate. It requires the insurer to authorise cashless treatment within one hour of the request. It requires discharge authorisation within three hours. It introduces a penalty of Rs. 5,000 per day for non-compliance with awards of the Insurance Ombudsman. And it makes claim repudiation, after five years of continuous coverage, impossible except on proven fraud or specifically declared permanent exclusions.

These are real reforms. They have changed the law. They have, in the past two years, given Indian patients a level of protection that did not exist a decade ago. But twelve is not enough.

The pace of medical innovation has outrun the regulator's list. Gene therapy is in the clinic. CAR-T cell therapy for haematological malignancies is in the clinic. Advanced robotic neurosurgery is in the clinic. New laser modalities are in the clinic. The regulatory list contains twelve. The roster of treatments that Indian medical regulators have approved, that are in routine use at Indian tertiary institutions, that Indian doctors are prescribing today, runs into hundreds. The regulatory architecture has captured the past. It has not yet captured the future. And the gap between the two is being filled, today, by the insurer's exclusion clause.

III. The line that must be drawn

There is a principle that the IRDAI must now state, in terms, and enforce. When a treatment has been approved by a competent medical regulator in India, whether the Central Drugs Standard Control Organisation, the Indian Council of Medical Research, the National Medical Commission, or by adoption into the standard protocols of the recognised tertiary institutions, the insurer cannot refuse coverage on the ground that the treatment is new, experimental, unproven, or not specifically listed in the policy. The medical regulator's approval pre-empts the insurer's contractual classification. The exclusion clause does not survive the regulatory determination.

This principle is already implicit in the 2020 definition of "Unproven or Experimental Treatment," which the IRDAI tied to "established medical practice in India." But it is implicit, not explicit. It is enforced episodically through litigation, not systemically through regulation. And the burden of the gap is carried by the patient, who does not have the time, the money, or the legal sophistication to challenge an insurer's denial when his treatment is scheduled for next week.

Consider what happens when the principle is not enforced. In Garima Singh v. New India Assurance Co. Ltd. & Ors., W.P.(C) 11799/2023, decided by the Hon'ble High Court of Delhi on 03.05.2024, a stage IV breast cancer patient with a Rs. 44.5 lakh policy was offered Rs. 2 lakh against an Rs. 11 lakh claim. The petitioner was undergoing chemo-immunotherapy, an emergent modality that combines chemotherapy with monoclonal antibody immunotherapy. The insurer treated this as falling within the policy's sub-limit on monoclonal antibody injections, capped at Rs. 2 lakh.

The Hon'ble High Court rejected the construction. It held that chemo-immunotherapy is a distinct modality, that the sub-limit drafted for monoclonal antibody injection did not extend to it, and that even on a reading of ambiguity, the rule of contra proferentem operates in favour of the insured. The insurer was directed to honour the Insurance Ombudsman's award in full and to pay costs of Rs. 50,000 for the harassment caused to the cancer patient.

That is one judgement, in one writ, for one petitioner who had the means and the determination to fight a multinational insurance company through the Delhi High Court while undergoing chemotherapy. The patient won. But she should not have had to fight. The clause-reading was indefensible from the start. The fight should never have begun.

The principle, if stated by the IRDAI in a binding circular, would have stopped the denial at the claims desk. The patient would have received her Rs. 11 lakh in the first week, not after a writ petition. The advocate's role would have been preventive, not reactive. The Court's docket would have been lighter. And the principle would have applied not only to Garima Singh, but to every other policyholder who was being denied the same treatment in the same way at the same moment.

This is what regulation does that litigation cannot. Regulation operates at scale. Litigation operates one case at a time. The citizen who wins her writ petition wins her own case. The citizen on the next floor of the same hospital, with the same denial in his pocket, must start his own case from the beginning. Multiply that by the population of policyholders in India, by the rising cost of modern medicine, by the demographic curve of an ageing country, and you arrive at the regulatory deficit this article is about.

IV. In the operating theatre

The reader may wonder why this should be a matter of public concern. The answer is in the operating theatre.

There is no reason today, in 2026, for an Indian patient with an enlarged prostate to be put through open prostatectomy when a Holmium laser enucleation or a Green laser vaporisation will achieve the same clinical result with less blood loss, shorter recovery, lower infection risk, and reduced hospital stay. The procedures are approved by the CDSCO. They are taught at AIIMS. They are practised in every major tertiary urology unit in India. They are the standard of care for a man over fifty with benign prostatic hyperplasia who has not responded to medical management. To put such a patient through open surgery, in the year 2026, is to take him back a decade in the practice of urology because the underwriter has not updated his list of covered procedures.

There is no reason for a patient with a cardiac condition to be put through invasive open-heart bypass when an angioplasty with drug-eluting stenting will do the work. The stents are approved. The cardiologists are trained. The procedure is performed in cathlabs across the country, in every metropolitan tertiary hospital and in every major district headquarters town. It is not a frontier procedure. It is routine cardiology. The patient is discharged in two or three days. He returns to office in three or four weeks. The alternative, the open bypass, requires a sternotomy, three months of restricted activity, a six-week catheterised recovery, and a risk profile that is materially higher in the elderly population that needs the procedure most.

There is no reason for a patient with a brain tumour, particularly a small to medium-sized lesion in a surgically difficult location, to undergo open craniotomy when stereotactic radio-surgery, delivered through Gamma Knife or CyberKnife, will reach the same lesion without the scalpel. The patient walks out the next morning. The recovery, measured in days rather than months, is a different order of human experience from the recovery from craniotomy. The cognitive deficits associated with the open procedure are largely absent in the stereotactic one. And yet, today, an Indian patient with the same diagnosis at the same hospital may receive the older procedure because his policy was written in 2018 and his insurer has not updated his exclusions.

There is no reason, as gene therapy comes of age over the next decade, for an Indian patient to be denied a one-time genetic intervention because the policy was written in 2018 and the underwriter has not learned to spell the names of the new molecules. The Indian regulatory apparatus will, in due course, approve specific gene therapies for specific indications. When that happens, the approval will be the determinative fact. The policy's failure to anticipate the treatment cannot defeat the regulator's approval of it.

The choice between the older modality and the newer one is not a budgeting choice. It is a clinical choice. It is made by the doctor on the basis of the patient's body, the patient's condition, the patient's prognosis, and the patient's circumstances. The insurer's job is to pay for whichever choice the doctor and the patient make, within the limits of the sum insured, subject to the standard regulatory exclusions, and without inserting a second classification of its own. If the regulator has approved the treatment, that is the end of the inquiry. The insurer pays. The patient receives the most effective available care. The doctor practises medicine. Each does its job. None of them does the other's.

V. The false economy of denial

There is a further point that deserves attention, and it is one the insurance industry would rather not discuss. The insurer's denial of the modern modality is presented as a cost-saving measure. The premium has been calculated on the basis of an older, cheaper procedure. The denial is, in effect, a refusal to absorb the cost of medical progress. The insurer's claims department reports its denials as savings to the insurer's combined ratio. The combined ratio is reported to the shareholders. The shareholders are pleased.

But this calculation is illusory. The total cost of the older procedure, when measured across the full arc of the patient's recovery, is often higher than the cost of the modern one.

A patient who undergoes open-heart bypass surgery requires a longer hospital stay, a longer convalescent period, and a higher risk of complications and readmissions. Each of these has a cost. The hospital bill for the longer stay is paid by someone, often the patient himself once the per-day sub-limit is exhausted. The complications, when they occur, are treated by someone, again often the patient. The readmissions, when they occur, are paid by someone. The lost productivity of the patient, in the months of restricted activity, is borne by his family. The total cost, summed across the system and not merely across the insurer's balance sheet, is often higher than the cost of the angioplasty with stenting that the insurer refused to pay for.

A patient who undergoes open prostatectomy faces a longer catheterisation period, a higher risk of incontinence, and a longer return to normal life. A patient who undergoes craniotomy in lieu of stereotactic radio-surgery loses weeks of working life and months of cognitive recovery. A patient who receives chemotherapy in lieu of targeted immunotherapy faces a different toxicity profile, often a worse one, and often requires more total cycles to achieve a comparable response. None of these costs appears on the insurer's claims register. All of them are real.

The insurer is not saving money by denying the modern modality. The insurer is shifting the cost. From itself to the patient. From the policy to the family. From the present to the future. From the financial system to the human one.

This is not insurance. This is the appearance of insurance. The structural function of insurance is to absorb a class of risks in exchange for a premium. When the insurer denies the very risks it has been paid to absorb, it is offering not protection but the resemblance of protection. The Constitution requires the regulator to ensure that what is sold to the citizen is the real thing.

VI. Three steps the IRDAI must take now

The IRDAI must now do three things. All three are within its existing statutory powers. None requires fresh legislation. None requires new authority. All three can be issued in the form of a circular before the end of the current financial year.

These three steps would cost the regulator nothing. They would require only the exercise of powers the regulator already holds, and that the Constitution requires it to exercise in the interest of the citizens it was created to protect.

VII. What to do if you are denied today

For the reader who is reading this in the middle of a claim dispute, the regulatory reform proposed above is not enough. The reform will arrive, if it arrives at all, in the form of a circular at some future date. The denial is on the desk now. The treatment is scheduled for next week. What is the path?

There are four forums available to an Indian policyholder, in ascending order of formality, and the choice of forum is everything.

The practical advice is this. Do not start with the consumer commission. Do not start with the civil court. Do not start with the writ unless the urgency is acute. Start with the grievance cell to build the record, register the Bima Bharosa complaint to create regulatory pressure, and then file with the Insurance Ombudsman. The Ombudsman, in 2026, is the workhorse of policyholder remedy in India. The time value of every rupee owed by the insurer to the patient is the only metric that matters in this field, and the Ombudsman is the route that returns that rupee fastest.

❖ ❖ ❖

A person buys insurance because she wants to be treated, properly, when she is ill. She does not buy it because she wants to be told, at the moment of crisis, that the procedure her doctor has prescribed is too modern for the company that took her premium for sixteen years.

The treatment is for the doctor to choose. The approval is for the medical regulator to give. The cover is for the insurer to honour. Each has its place. The trouble begins when the insurer tries to do all three. It is time the regulator put that to an end.

Watch · The Office on YouTube

Two-minute explainers on the questions these essays raise.

The Office publishes short video versions of its long-form writing. Subscribe to be notified when the explainer for this article is released.

Sources and provisions referred to

Statutes and rules

Cases

Official documents

Frequently asked questions

Can a health insurer refuse to cover a treatment that India's medical regulators have approved?

The article's position is that it should not survive challenge. Where the CDSCO has approved a device or drug, the ICMR has recognised a protocol, or the NMC's standards treat a procedure as accepted practice, an exclusion clause drafted years before that determination should yield to it. The regulator decides what counts as medicine in India; the underwriter prices risk. When the two conflict, the article argues the regulatory determination must prevail, because the alternative is an insurance product that promises treatment and delivers only yesterday's version of it.

What should a policyholder do when a claim for an advanced procedure is denied?

Move in sequence and build a record. First, obtain the denial in writing with the specific clause relied upon. Second, secure the treating doctor's reasoned recommendation explaining why this procedure, rather than the older alternative, is medically indicated. Third, escalate to the insurer's grievance redressal officer, who must respond within the timelines the IRDAI prescribes. Fourth, if the denial stands, approach the Insurance Ombudsman or the consumer commission. Every step is stronger if the paper trail from the first step is complete.

Does the IRDAI have a duty to act against outdated exclusion clauses?

The article argues that it does, and that the duty has a constitutional colour. The right to health has been read into Article 21, and the IRDAI is the state's instrument in the insurance sector. Its standardisation of exclusions in 2019 and the consolidation in the 2024 master circular show the regulator can move policy wordings toward current medical science. The article treats those reforms as the beginning of the exercise, and presses for the next step: a standing mechanism that updates coverage as the medical regulators approve new treatments.

When should a policyholder approach the Insurance Ombudsman, and what can it award?

After the insurer's own grievance process has failed or lapsed. The Ombudsman is a free, relatively fast forum designed for individual policyholders, which can award compensation up to the ceiling fixed under the rules, presently Rs. 50 lakh. It can award the claim amount with interest, and insurers are bound to comply within fixed timelines. For claims above the ceiling, or where wider declaratory relief is needed, the consumer commission or a writ petition becomes the appropriate route.

What are 'modern treatments' and must my policy cover them?

The IRDAI's 2019 standardisation required health policies to cover a defined list of modern treatments, including procedures such as robotic surgery, immunotherapy, and oral chemotherapy, subject to disclosed sub-limits. The 2024 master circular carried that consolidation further. If your policy was issued or renewed after these reforms, a blanket refusal to cover a listed modern treatment is contrary to the regulator's mandate, and the denial should be challenged through the grievance ladder set out above.

These answers are educational summaries of the article above; they are not legal advice on any individual matter.

Corrections: if you find an error of law or fact in this article, write to contact@lokeshbhardwajlawoffices.com with the subject 'Correction'. Corrections are made in the text and noted here with the date.

Disclaimer

This article is offered as general legal commentary for informational and educational purposes only and does not constitute legal advice. References are to the Constitution of India, the Insurance Act, 1938, the IRDA Act, 1999, the Drugs and Cosmetics Act, 1940, the Insurance Ombudsman Rules, 2017, the IRDAI Guidelines on Standardisation of Exclusions dated 27.09.2019, and the Master Circular on Health Insurance Business dated 29.05.2024, together with the authorities cited. The interpretation of insurance contracts, regulatory circulars, and judicial precedents is fact-specific. Readers facing a claim dispute should consult qualified counsel before initiating any action. Published in compliance with the Bar Council of India Rules, Chapter II, Part VI, Rule 36. No part of this article is intended to solicit professional engagement.

WhatsApp